Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkins Lymphoma

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 31, pages 775–782 (2003)Cite this article

Summary:

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab–CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment. Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications. One patient withdrew consent after achieving complete remission (CR) prior to HDT. One patient was taken off study with signs of disease progression after induction treatment. All patients showed stable engraftment after HDT. Response rates appear to be favorable, indicating an additional effect of rituximab and HDT. Overall, 12 of 13 patients achieved CR/CRu and one patient partial remission. Follow-up of immune reconstitution displayed transient severe combined immunodeficiency with slow normalization of the cellular and humoral compartments without a significant increase of infectious complications. Taken together, high-dose chemotherapy can be safely given following treatment with CHOP+rituximab. Efficacy in this small cohort of patients was encouraging with sustained remissions in both FCL and MCL patients. Upfront HDT should be considered as a therapeutic option especially in young and/or high-risk patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499–1505.

    Article  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  3. Linassier C, Fouillared L, Milpied N et al. Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional therapy: a ‘France Autogreffe’ study. Cancer Detect Prov 1996; 20: 11–19.

    CAS  Google Scholar 

  4. Freedmann AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786.

    Google Scholar 

  5. Hiddemann W, Unterhalt IM, Wandt H et al. Myeloablative radiochemotherapy followed by blood-stem cell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized comparison by the German Low-grade Lymphoma Study Group (GLSG). Blood 1999; 94: 2715 (Abstr.).

    Google Scholar 

  6. Horning S, Negrin R, Hoppe R et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission. Results of a phase II clinical trial. Blood 2001; 97: 404–409.

    Article  CAS  Google Scholar 

  7. Gribben J, Freedman A, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.

    Article  CAS  Google Scholar 

  8. Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786.

    CAS  Google Scholar 

  9. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  Google Scholar 

  10. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195.

    CAS  Google Scholar 

  11. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimaeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

    Article  CAS  Google Scholar 

  12. Foran JM, Gupta RK, Cunningham D et al. A UK multicenter phase II study of Rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81–88.

    Article  CAS  Google Scholar 

  13. Hainsworth JD, Burries HA, Morrissea LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low grade non-Hodgkin lymphoma. Blood 2000; 95: 3052–3056.

    CAS  Google Scholar 

  14. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106.

    Article  CAS  Google Scholar 

  15. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of Rituximab (chimaeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317–324.

    Article  CAS  Google Scholar 

  16. Vose JM, Link BK, Grossbard ML et al. Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397.

    Article  CAS  Google Scholar 

  17. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276.

    Article  CAS  Google Scholar 

  18. Hiddemann W, Forstpointner R, Fiedler F et al. The addition of Rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantle cell lymphomas (MCL) – results of a prospective randomized comparison of the German Low Grade Lymphoma Study Group GLSG). Blood 2001; 98: 3507 (Abstract).

    Google Scholar 

  19. Czuczman MS, Grillo-López AJ, White CA et al. Progression-free survival (PFS) after six years (median) follow up of the first clinical trial of Rituximab/CHOP chemoimmunotherapy. Blood 2001; 98: 2519 (Abstr.).

    Google Scholar 

  20. Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  Google Scholar 

  21. Rohatiner AZS, Freedman A, Nadler L et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 1994; 5 (Suppl. 2): S143–S146.

    Article  Google Scholar 

  22. Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with rituximab mobilization of in vivo purged stem cell, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235.

    Article  CAS  Google Scholar 

  23. Flohr T, Hess G, Kolbe K et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769–775.

    Article  CAS  Google Scholar 

  24. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729–735.

    Article  CAS  Google Scholar 

  25. Flinn IW, Jones RJ, Goodrich A et al. Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assay. Blood 2001; 98: 2832 (Abstr.).

    Google Scholar 

  26. Flinn IW, O'Donnell PV, Goodrich A et al. Peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632.

    Article  CAS  Google Scholar 

  27. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.

    CAS  Google Scholar 

  28. Majolino I, Pearce R, Taghipour G, Goldstone AH . Peripheral blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509–517.

    Article  CAS  Google Scholar 

  29. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  Google Scholar 

  30. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.

    Article  CAS  Google Scholar 

  31. Nicholson J, Hearn T, Cross G et al. revised guidelines for performing CD4+ T-cell determination in persons infected with human immunodeficiency virus. MMWR 1997; 46: 1–27.

    Google Scholar 

  32. Pott C, Tiemann M, Linke B et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998; 12: 1630–1637.

    Article  CAS  Google Scholar 

  33. Kaplan F, Meier P . Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 52: 457–481.

    Article  Google Scholar 

  34. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with Rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 115–122.

    CAS  Google Scholar 

  35. Gianni AM, Cortelazzo S, Magni M, Martelli M . Riuximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29 (Suppl. 1): S10–S13.

    Article  Google Scholar 

  36. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029–4035.

    CAS  Google Scholar 

  37. Boeckh M, Stevens-Ayers T, Bowden RA . Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996; 174: 907–912.

    Article  CAS  Google Scholar 

  38. Goldberg SL, Pecora AL, Alter RS et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486–1888.

    Article  CAS  Google Scholar 

  39. Nagafuji K, Eto T, Hayashi S et al. Fatal cytomegalovirus interstitial pneumonia following autologous peripheral blood stem cell transplantation. Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1998; 21: 301–303.

    Article  CAS  Google Scholar 

  40. Horwitz S, Breslin S, Negrin R et al. Adjuvant rituximab after autologous peripheral blood stem cell transplantation results in delayed immune reconstitution without increase in infectious complications. Blood 2000; 96: 384a.

    Google Scholar 

  41. Kolbe K, Domkin D, Derigs HG et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143–147.

    Article  CAS  Google Scholar 

  42. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294.

    Article  CAS  Google Scholar 

  43. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862.

    Article  CAS  Google Scholar 

  44. Maloney DG, Press OW, Braziel RM et al. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Blood 2001; 98: 3502 (Abstr.).

    Google Scholar 

  45. Piro LK, White AJ, Grillo-Lopez et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–661.

    Article  CAS  Google Scholar 

  46. Ghielmini M, Schmitt SF, Cogliatti AB et al. Maintenance treatment with 2-monthly rituximab after standard weekly × 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Ann Oncol 2002; 13 (Suppl 2): 112 (Abstr.).

    Google Scholar 

  47. Czuczman MS, Fallon A, Mohr A et al. Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report. Blood 2001; 98: 2518 (Abstr.).

    Article  Google Scholar 

  48. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526.

    Article  CAS  Google Scholar 

  49. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–1178.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge study management by Gertrud Feldmann and the excellent technical assistance of Karola Schmidt. The Deutsche Krebshilfe supported this study, Grant Numbers 70-2427 and 70-2428.

Author information

Authors and Affiliations

  1. IIIrd Department of Medicine, Johannes Gutenberg-University, Mainz, Germany

    G Heß, T Flohr, C Huber, K Kolbe, H-G Derigs & T Fischer

Authors
  1. G Heß
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Flohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Kolbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H-G Derigs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heß, G., Flohr, T., Huber, C. et al. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplant 31, 775–782 (2003). https://doi.org/10.1038/sj.bmt.1703925

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703925

Keywords

This article is cited by

Search

Advanced search

Quick links